Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.
Saved in:
| Title: | Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial. |
|---|---|
| Authors: | Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hyrien O; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Roels S; Johnson & Johnson Innovative Medicine, Beerse, Belgium., Stieh DJ; Janssen Vaccines and Prevention, Leiden, the Netherlands.; Vaccine Company Inc., South San Francisco, CA, USA., Van Dromme I; Johnson & Johnson Innovative Medicine, Beerse, Belgium., Van Roey GA; Janssen Vaccines and Prevention, Leiden, the Netherlands., Kenny A; Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA.; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.; Duke Global Health Institute, Duke University, Durham, NC, USA., Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA., Carone M; Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA., McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Sanofi Vaccines R&D, Marcy l'étoile, France., Houchens CR; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Martins K; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Jayashankar L; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Castellino F; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Amoa-Awua O; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Basappa M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Flach B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Moore C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Naisan M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Naqvi M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Narpala S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mueller A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Serebryannyy L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Castro M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Wang J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Petropoulos CJ; LabCorp-Monogram Biosciences, South San Francisco, CA, USA., Luedtke A; Department of Statistics, University of Washington, Seattle, WA, USA., Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Juraska M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA., Wolfe DN; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Sadoff J; Janssen Vaccines and Prevention, Leiden, the Netherlands.; Centivax, South San Francisco, CA, USA., Gray GE; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; South African Medical Research Council, Cape Town, South Africa., Grinsztejn B; Evandro Chagas National Institute of Infectious Diseases-Fundação Oswaldo Cruz, Rio de Janeiro, Brazil., Goepfert PA; Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Bekker LG; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, Cape Town, South Africa.; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Gaur AH; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA., Veloso VG; Evandro Chagas National Institute of Infectious Diseases-Fundação Oswaldo Cruz, Rio de Janeiro, Brazil., Randhawa AK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hendriks J; Janssen Vaccines and Prevention, Leiden, the Netherlands., Truyers C; Johnson & Johnson Innovative Medicine, Beerse, Belgium., Vandebosch A; Johnson & Johnson Innovative Medicine, Beerse, Belgium.; argenx BV, Ghent, Belgium., Struyf F; Johnson & Johnson Innovative Medicine, Beerse, Belgium.; GSK, Wavre, Belgium., Schuitemaker H; Janssen Vaccines and Prevention, Leiden, the Netherlands.; Valneva, Saint-Herblain, France., Douoguih M; Janssen Vaccines and Prevention, Leiden, the Netherlands.; Merck, Rahway, NJ, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.; Fogarty International Center, Bethesda, MD, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Donis RO; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA. pgilbert@fredhutch.org. |
| Corporate Authors: | Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team, United States Government (USG)/CoVPN Biostatistics Team |
| Source: | Nature communications [Nat Commun] 2024 Nov 12; Vol. 15 (1), pp. 9785. Date of Electronic Publication: 2024 Nov 12. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-53727-y |
